Z穴位注射丹参注射液治疗慢性阻塞性肺疾病缓解期34例

目的 观察穴位注射丹参注射液治疗慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）缓解期的临床疗效。方法 将68例COPD缓解期患者随机单盲分为治疗组34例及对照组34例，治疗组在常规综合治疗基础上加用丹参注射液穴位注射（选穴：定喘、肺俞、肾俞、脾俞、足三里），每周1次，3个月为1个疗程；对照组采用常规综合治疗，治疗3个月。两组患者均在治疗前后使用COPD评估测试（COPD assessment test TM，CAT）进行评分，并检测第1秒用力肺活量(forced expiratory volume in one second，FEV1)及其占预计值的百分比(FEV1%)、FEV1与用力肺活量（forced vital capacity，FVC）的比值（FEV1／FVC），及检测血液T细胞亚群（CD4+、CD8+、CD4+/CD8+）的变化情况。 结果 治疗后治疗组CAT评分显著低于对照组（P<0.01）；CD4+ T细胞百分比、CD4+/CD8+比值显著高于对照组(P<0.05，或P<0.01)，CD8+ T细胞百分比显著低于对照组(P<0.01)。治疗后治疗组FEV1、FEV1%、FEV1／FVC显著高于对照组（P<0.01）。结论 在常规治疗基础上穴位注射丹参注射液可以改善COPD缓解期患者生活质量，改善肺通气功能，提高患者免疫力。

Clinical Effect of Acupoint Injection of Salvia Miltiorrhiza on Stable Chronic Obstructive Pulmonary Disease: An Analysis of 34 Cases

Objective To observe the clinical effect of acupoint injection of Salvia miltiorrhiza on stable chronic obstructive pulmonary disease (COPD). Methods Sixty-eight patients with stable COPD were divided into treatment group (n=34) and control group (n=34) in a single-blind randomised controlled trial. The treatment group received injection of Salvia miltiorrhiza at the acupoints of Dingchuan, Feishu, Shenshu, Pishu, and Zusanli on the basis of routine comprehensive treatment once per week for three months. The control group received routine comprehensive treatment for three months. Before and after treatment, both groups underwent COPD assessment test (CAT), and the forced expiratory volume in one second (FEV1), FEV1%, FEV1/forced vital capacity (FVC), CD4+ and CD8+ percentages, and CD4+/CD8+ were measured or calculated. Results Compared with the control group, the treatment group showed significantly lower CAT scores (P<0.01), significantly higher CD4+ percentage and CD4+/CD8+(P<0.05, or P<0.01), significantly lower CD8+ percentage (P<0.01), and significantly higher FEV1, FEV1%, and FEV1/FVC (P<0.01). Conclusion Acupoint injection of Salvia miltiorrhiza on the basis of routine comprehensive treatment can improve the quality of life, pulmonary ventilation function, and immunity of the patients with stable COPD.